Capricor Therapeutics' cell remedy for the Duchenne muscular dystrophy has fallen to the FDA, whereby the regulator rejects the applying of the biotech searching for the approval of the rules of what the corporate can be the primary remedy developed for the heart problems of those uncommon. The complete response letter of the FDA said that the applying for the […]
